Trends in discovery of new drugs for tuberculosis therapy

被引：36

作者：

Riccardi, Giovanna ^{[1
]}

Pasca, Maria Rosalia ^{[1
]}

机构：

[1] Univ Pavia, Dept Biol & Biotechnol Lazzaro Spallanzani, I-27100 Pavia, Italy

来源：

JOURNAL OF ANTIBIOTICS | 2014年 / 67卷 / 09期

关键词：

KILL MYCOBACTERIUM-TUBERCULOSIS; RESISTANT TUBERCULOSIS; TRANS-TRANSLATION; ATP SYNTHASE; IN-VITRO; PYRAZINAMIDE; RIFAPENTINE; INHIBITORS; TARGET; MMPL3;

D O I：

10.1038/ja.2014.109

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

After the introduction of isoniazid and rifampicin, the second one discovered in the Lepetit Research Laboratories (Milan, Italy), under the supervision of Professor Piero Sensi, tuberculosis (TB) was considered an illness of the past. Unfortunately, this infectious disease is still a global health fear, due to the multidrug-resistant Mycobacterium tuberculosis and extensively circulating drug-resistant strains, as well as the unrecognized TB transmission, especially in regions with high HIV incidence. In the last few years, new antitubercular molecules appeared on the horizon both in preclinical and clinical stage of evaluation. In this review, we focus on a few of them and on their mechanism of action. Two new promising drug targets, DprE1 and MmpL3, are also discussed.

引用

页码：655 / 659

页数：5

共 66 条

[1] A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].

Andries, K ;

Verhasselt, P ;

Guillemont, J ;

Göhlmann, HWH ;

Neefs, JM ;

Winkler, H ;

Van Gestel, J ;

Timmerman, P ;

Zhu, M ;

Lee, E ;

Williams, P ;

de Chaffoy, D ;

Huitric, E ;

Hoffner, S ;

Cambau, E ;

Truffot-Pernot, C ;

Lounis, N ;

Jarlier, V .

SCIENCE, 2005, 307 (5707) :223-227

[2]

[Anonymous], 2013, WHO GLOB TUB REP 201

[3] Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors [J].

Batt, Sarah M. ;

Jabeen, Talat ;

Bhowruth, Veemal ;

Quill, Lee ;

Lund, Peter A. ;

Eggeling, Lothar ;

Alderwick, Luke J. ;

Fuetterer, Klaus ;

Besra, Gurdyal S. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (28) :11354-11359

[4] Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: an update [J].

Blair, Jessica M. A. ;

Piddock, Laura J. V. .

CURRENT OPINION IN MICROBIOLOGY, 2009, 12 (05) :512-519

[5] Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Tuberculosis [J].

Chahine, Elias B. ;

Karaoui, Lamis R. ;

Mansour, Hanine .

ANNALS OF PHARMACOTHERAPY, 2014, 48 (01) :107-115

[6] A review of tuberculosis: Focus on bedaquiline [J].

Chan, Bonnie ;

Khadem, Tina M. ;

Brown, Jack .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (22) :1984-1994

[7] An update on the use of rifapentine for tuberculosis therapy [J].

Chan, John Gar Yan ;

Bai, Xiaoxue ;

Traini, Daniela .

EXPERT OPINION ON DRUG DELIVERY, 2014, 11 (03) :421-431

[8] High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for Intracellular Antimycobacterial Inhibitors [J].

Christophe, Thierry ;

Jackson, Mary ;

Jeon, Hee Kyoung ;

Fenistein, Denis ;

Contreras-Dominguez, Monica ;

Kim, Jaeseung ;

Genovesio, Auguste ;

Carralot, Jean-Philippe ;

Ewann, Fanny ;

Kim, Eun Hye ;

Lee, Sae Yeon ;

Kang, Sunhee ;

Seo, Min Jung ;

Park, Eun Jung ;

Skovierova, Henrieta ;

Pham, Ha ;

Riccardi, Giovanna ;

Nam, Ji Youn ;

Marsollier, Laurent ;

Kempf, Marie ;

Joly-Guillou, Marie-Laure ;

Oh, Taegwon ;

Shin, Won Kyung ;

No, Zaesung ;

Nehrbass, Ulf ;

Brosch, Roland ;

Cole, Stewart T. ;

Brodin, Priscille .

PLOS PATHOGENS, 2009, 5 (10)

[9] Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients [J].

Diacon, Andreas H. ;

Dawson, Rodney ;

Hanekom, Madeleine ;

Narunsky, Kim ;

Maritz, Stefan J. ;

Venter, Amour ;

Donald, Peter R. ;

van Niekerk, Christo ;

Whitney, Karl ;

Rouse, Doris J. ;

Laurenzi, Martino W. ;

Ginsberg, Ann M. ;

Spigelman, Melvin K. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (08) :3402-3407

[10] Safety and Pharmacokinetics of Escalating Daily Doses of the Antituberculosis Drug Rifapentine in Healthy Volunteers [J].

Dooley, K. E. ;

Bliven-Sizemore, E. E. ;

Weiner, M. ;

Lu, Y. ;

Nuermberger, E. L. ;

Hubbard, W. C. ;

Fuchs, E. J. ;

Melia, M. T. ;

Burman, W. J. ;

Dorman, S. E. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (05) :881-888

← 1 2 3 4 5 6 7 →